Modified Bufei Decoction to relieve post-surgery symptoms and support recovery for older lung cancer patients
Official title: A Randomized Controlled Multicenter Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery
Run by Peking University Cancer Hospital & Institute · NCT06674252 · Data updated 2026-11-12
This trial tests whether taking modified Bufei Tang granules twice daily for 28 days can reduce post-surgery cough, breathlessness, and fatigue in people aged 65 and older who had lung cancer surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 65 Years and up |
| Sex | All |
| Enrollment | 174 (estimated) |
| Sponsor | Peking University Cancer Hospital & Institute Academic / other |
| Locations | 2 sites (Beijing, Beijing Municipality and 1 other locations) |
| Status | Recruiting |
| Started | June 13, 2025 |
| Main results expected | September 2027 |
| Study ends | December 2027 |
| Registry record updated | January 27, 2026 |
| Trial ID | NCT06674252 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients aged 65 or older who have confirmed postoperative lung cancer, meet the MDASI-TCM symptom thresholds (any one of cough, fatigue, shortness of breath ≥4 or the three combined ≥6), have generally stable heart and liver/kidney labs, and fit the TCM pattern of lung‑and‑kidney deficiency.
✕Probably not a fit
Patients with severe pulmonary infections, significant psychiatric illness or depression, those without the target post-operative symptoms, or those with unstable organ function are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter, randomized, double-blind, placebo-controlled trial enrolls older patients with persistent postoperative symptoms after lung cancer resection and randomizes them 1:1 to active Jiawei Bufei Tang granules or matching placebo. Treatment begins around day 7 after surgery and continues for 28 days, with one packet taken orally twice a day. Symptom changes are measured using the MDASI-TCM scale for cough, shortness of breath, and fatigue before and after treatment to compare differences between groups. The herbal formula is provided as standardized non-decoction granules and the placebo is matched for appearance and taste to preserve blinding.
Why it matters
Potential benefit: If effective, the herbal treatment could reduce common post-surgery symptoms like cough, breathlessness, and fatigue and improve short-term recovery and quality of life.
How similar studies have gone: Related traditional Chinese medicine formulations have shown mixed results in small trials, and high-quality randomized evidence for this specific formula is limited, so the approach is promising but not yet proven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Patients with postoperative lung cancer who have clear histological or cytological diagnosis.
* Age ≥ 65 years old, both male and female are eligible. According to the MDASI-TCM scale evaluation, any of the three symptoms of cough, fatigue, and shortness of breath should score ≥ 4 points, or the sum of the three should score ≥ 6 points.
* The heart function is basically normal; ALT/AST is within 2 times the normal value; SCr is within the normal range.
Traditional Chinese medicine syndrome differentiation is characterized by deficiency of both lungs and kidneys.
Exclusion Criteria:
* Patients with severe pulmonary infections. ⑵. Patients with mental illness. ⑶. Patients with depression.
Where it's running
-
Beijing cancer hospital
Beijing, Beijing Municipality, China Recruiting -
Beijing cancer hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Xu yi chen, MD
- Email: xxxxyc@126.com
- Phone: 0086+15801096968
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Shape-sensing robotic bronchoscopy to diagnose peripheral lung nodules
This tests a shape-sensing robotic bronchoscopy to see if it can get tissue samples from adults in Korea with peripheral lung nodules.
-
AVZO-1418 alone and with other treatments for advanced epithelial solid tumors
This trial will test whether intravenous AVZO-1418, alone or with other cancer drugs, is safe and helps adults with locally advanced or metastatic epithelial solid tumors, including some lung cancers.
-
Online and in-person exercise programs for cancer survivors in Canada
This study is testing whether online and in-person exercise programs can help cancer survivors in Canada stay active and improve their health.
-
General anesthesia versus conscious sedation for radial endobronchial ultrasound
This trial will see if general anesthesia or conscious sedation gives better diagnostic results for adults undergoing radial endobronchial ultrasound to sample peripheral lung nodules.
-
Super1 TCR-T for NY-ESO-1–positive advanced solid tumors
This trial tests whether a single infusion of Super1 TCR-T can help people with advanced sarcoma, lung cancer, or melanoma whose tumors are HLA-A*02 positive and express NY-ESO-1.
-
Using a new molecular probe for early diagnosis of tumors
This study is testing a new imaging tool to see if it can help doctors find different types of tumors earlier in patients aged 18 to 75 who already have confirmed tumor lesions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.